They analyzed the prognostic impact of APL with alternative RARA or RARG fusions, showing that the 3-year overall survival (OS) and leukemia-free survival (LFS) of APL with alternative RARA or RARG were worse than that of PML-RARA cohort. The gene discussed is RARA; the disease is acute promyelocytic leukemia.